Welcome to Avanir Clinical Trials

Agitation in Alzheimer’s Disease (AD)

Who can enroll in the study?

  • Diagnosed with Alzheimer's Disease (AD)
  • Have symptoms of irritability, agitation, aggression or anger that are disruptive of the daily routine
  • Are between the ages of 50-90
  • Have a caregiver available for study participation
  • Have stable health
  • No cost for study participation
Pseudobulbar affect Registry Investigating Symptom Management

Who can enroll in the study?

  • PRISM II is a 12 week long study testing the safety and effectiveness of NUEDEXTA (dextromethorphan HBr and quinidine sulfate) Capsules, 20mg/10mg in the treatment of pseudobulbar affect (PBA) in post stroke, dementia and traumatic brain injury (TBI) patients.
NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) 20mg/10mg capsules can interact with other medications and cause serious side effects. NUEDEXTA is contraindicated in patients taking certain drugs and in patients with specific cardiovascular risk factors. These are not all the risks from use of NUEDEXTA. Please see the Important Safety Information and full Prescribing Information
Levodopa Induced Dyskinesia in PARKINSON’S DISEASE

Who can enroll in the study?

  • Diagnosed with Parkinson's Disease (PD)
  • Dyskinesia of at least moderate severity
  • Levodopa induced dyskinesia (LID) present greater than 25% of the day
  • Between the ages of 30-80
  • Have stable health
  • No cost for study participation
AGITATION in AD
PRISM II
Levodopa Induced Dyskinesia in PARKINSON’S DISEASE